Stem definition | Drug id | CAS RN |
---|---|---|
pituitary hormone-release stimulating peptides | 1559 | 53714-56-0 |
Dose | Unit | Route |
---|---|---|
60 | mcg | implant |
1 | mg | P |
0.13 | mg | P |
Property | Value | Reference |
---|---|---|
BDDCS (Biopharmaceutical Drug Disposition Classification System) | 1 | Benet LZ, Broccatelli F, Oprea TI |
S (Water solubility) | 250 mg/mL | Benet LZ, Broccatelli F, Oprea TI |
EoM (Fraction excreted unchanged in urine) | 2 % | Benet LZ, Broccatelli F, Oprea TI |
MRTD (Maximum Recommended Therapeutic Daily Dose) | 0.01 ยตM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
Vd (Volume of distribution) | 0.38 L/kg | Lombardo F, Berellini G, Obach RS |
CL (Clearance) | 2 mL/min/kg | Lombardo F, Berellini G, Obach RS |
fu (Fraction unbound in plasma) | 0.54 % | Lombardo F, Berellini G, Obach RS |
t_half (Half-life) | 2.90 hours | Lombardo F, Berellini G, Obach RS |
Date | Agency | Company | Orphan |
---|---|---|---|
May 24, 2022 | EMA | ACCORD HEALTHCARE S.L.U. | |
April 9, 1985 | FDA |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Intercepted product preparation error | 757.83 | 17.04 | 127 | 13132 | 384 | 56278424 |
Hot flush | 712.45 | 17.04 | 302 | 12957 | 46424 | 56232384 |
Syringe issue | 635.28 | 17.04 | 141 | 13118 | 2315 | 56276493 |
Endometriosis | 588.23 | 17.04 | 150 | 13109 | 4552 | 56274256 |
Occupational exposure to product | 413.83 | 17.04 | 96 | 13163 | 1934 | 56276874 |
Pelvic pain | 391.90 | 17.04 | 135 | 13124 | 11732 | 56267076 |
Device leakage | 368.59 | 17.04 | 111 | 13148 | 6264 | 56272544 |
Ovarian hyperstimulation syndrome | 338.74 | 17.04 | 92 | 13167 | 3572 | 56275236 |
Vaginal haemorrhage | 272.39 | 17.04 | 129 | 13130 | 25544 | 56253264 |
Off label use | 213.10 | 17.04 | 428 | 12831 | 555752 | 55723056 |
Heavy menstrual bleeding | 204.87 | 17.04 | 92 | 13167 | 16117 | 56262691 |
Uterine leiomyoma | 182.26 | 17.04 | 70 | 13189 | 8272 | 56270536 |
Abscess sterile | 173.21 | 17.04 | 26 | 13233 | 26 | 56278782 |
Injury associated with device | 166.93 | 17.04 | 52 | 13207 | 3281 | 56275527 |
Injection site abscess | 157.36 | 17.04 | 39 | 13220 | 1047 | 56277761 |
Hysterectomy | 142.14 | 17.04 | 59 | 13200 | 8532 | 56270276 |
Mood swings | 118.42 | 17.04 | 64 | 13195 | 16683 | 56262125 |
Wrong technique in product usage process | 108.79 | 17.04 | 98 | 13161 | 58070 | 56220738 |
Intermenstrual bleeding | 102.06 | 17.04 | 44 | 13215 | 6983 | 56271825 |
Oestradiol increased | 82.81 | 17.04 | 15 | 13244 | 79 | 56278729 |
Menstrual disorder | 76.96 | 17.04 | 32 | 13227 | 4643 | 56274165 |
Injection site abscess sterile | 76.11 | 17.04 | 11 | 13248 | 6 | 56278802 |
Ovarian cyst | 76.04 | 17.04 | 46 | 13213 | 14820 | 56263988 |
Dysmenorrhoea | 71.67 | 17.04 | 28 | 13231 | 3458 | 56275350 |
Uterine haemorrhage | 71.25 | 17.04 | 28 | 13231 | 3512 | 56275296 |
Rheumatoid arthritis | 70.93 | 17.04 | 5 | 13254 | 382599 | 55896209 |
Epiphysiolysis | 68.49 | 17.04 | 11 | 13248 | 23 | 56278785 |
Haemorrhage | 66.52 | 17.04 | 74 | 13185 | 56323 | 56222485 |
Injection site pain | 65.87 | 17.04 | 107 | 13152 | 117011 | 56161797 |
Surgery | 57.30 | 17.04 | 53 | 13206 | 32433 | 56246375 |
Depression | 52.76 | 17.04 | 125 | 13134 | 179992 | 56098816 |
Anger | 51.80 | 17.04 | 33 | 13226 | 11639 | 56267169 |
Amenorrhoea | 51.69 | 17.04 | 30 | 13229 | 8956 | 56269852 |
Night sweats | 50.18 | 17.04 | 55 | 13204 | 41158 | 56237650 |
Abdominal pain | 49.08 | 17.04 | 153 | 13106 | 258652 | 56020156 |
Endometrial stromal sarcoma | 48.00 | 17.04 | 8 | 13251 | 23 | 56278785 |
Breast cancer metastatic | 47.86 | 17.04 | 35 | 13224 | 15434 | 56263374 |
Focal nodular hyperplasia | 47.75 | 17.04 | 13 | 13246 | 508 | 56278300 |
Suicidal ideation | 47.27 | 17.04 | 63 | 13196 | 57679 | 56221129 |
Vulvovaginal dryness | 44.41 | 17.04 | 18 | 13241 | 2447 | 56276361 |
Fall | 43.51 | 17.04 | 15 | 13244 | 357495 | 55921313 |
Joint swelling | 41.16 | 17.04 | 9 | 13250 | 289791 | 55989017 |
Product dispensing error | 40.63 | 17.04 | 26 | 13233 | 9238 | 56269570 |
Migraine | 40.46 | 17.04 | 73 | 13186 | 86724 | 56192084 |
Aplastic anaemia | 39.01 | 17.04 | 25 | 13234 | 8903 | 56269905 |
Blood luteinising hormone increased | 37.96 | 17.04 | 8 | 13251 | 101 | 56278707 |
Infusion related reaction | 37.90 | 17.04 | 3 | 13256 | 208928 | 56069880 |
Adnexa uteri pain | 36.85 | 17.04 | 10 | 13249 | 386 | 56278422 |
Hepatic cytolysis | 36.77 | 17.04 | 26 | 13233 | 10880 | 56267928 |
Pneumonia | 36.14 | 17.04 | 26 | 13233 | 407072 | 55871736 |
Ovarian cyst ruptured | 34.89 | 17.04 | 12 | 13247 | 1033 | 56277775 |
Injection site mass | 34.76 | 17.04 | 30 | 13229 | 16763 | 56262045 |
Neoplasm progression | 34.32 | 17.04 | 40 | 13219 | 31976 | 56246832 |
Neuroendocrine breast tumour | 33.38 | 17.04 | 6 | 13253 | 30 | 56278778 |
Blood follicle stimulating hormone abnormal | 33.31 | 17.04 | 5 | 13254 | 5 | 56278803 |
Adnexal torsion | 32.45 | 17.04 | 9 | 13250 | 377 | 56278431 |
Maternal exposure before pregnancy | 32.05 | 17.04 | 20 | 13239 | 6803 | 56272005 |
Metastases to liver | 31.98 | 17.04 | 32 | 13227 | 21554 | 56257254 |
Toxicity to various agents | 31.82 | 17.04 | 7 | 13252 | 224557 | 56054251 |
Headache | 31.46 | 17.04 | 232 | 13027 | 558812 | 55719996 |
Product leakage | 31.26 | 17.04 | 10 | 13249 | 687 | 56278121 |
Menstruation irregular | 30.68 | 17.04 | 19 | 13240 | 6377 | 56272431 |
Depressed mood | 30.25 | 17.04 | 40 | 13219 | 36319 | 56242489 |
Insomnia | 29.70 | 17.04 | 106 | 13153 | 191754 | 56087054 |
Dyspareunia | 29.08 | 17.04 | 13 | 13246 | 2247 | 56276561 |
Product physical consistency issue | 28.94 | 17.04 | 9 | 13250 | 564 | 56278244 |
Abdominal discomfort | 28.34 | 17.04 | 15 | 13244 | 277259 | 56001549 |
Dental fistula | 28.24 | 17.04 | 9 | 13250 | 611 | 56278197 |
Breast enlargement | 27.46 | 17.04 | 11 | 13248 | 1450 | 56277358 |
Precocious puberty | 27.30 | 17.04 | 7 | 13252 | 216 | 56278592 |
Leiomyosarcoma recurrent | 26.64 | 17.04 | 4 | 13255 | 4 | 56278804 |
Blood luteinising hormone decreased | 26.51 | 17.04 | 5 | 13254 | 34 | 56278774 |
Prosopagnosia | 26.38 | 17.04 | 5 | 13254 | 35 | 56278773 |
Adhesion | 25.83 | 17.04 | 10 | 13249 | 1205 | 56277603 |
Uterine adhesions | 25.27 | 17.04 | 5 | 13254 | 45 | 56278763 |
Vision blurred | 24.71 | 17.04 | 58 | 13201 | 82885 | 56195923 |
Drug intolerance | 24.69 | 17.04 | 16 | 13243 | 264802 | 56014006 |
Genital haemorrhage | 24.63 | 17.04 | 17 | 13242 | 6845 | 56271963 |
Calcium deficiency | 23.88 | 17.04 | 9 | 13250 | 1008 | 56277800 |
Injection site induration | 23.33 | 17.04 | 18 | 13241 | 8597 | 56270211 |
Myomectomy | 22.98 | 17.04 | 4 | 13255 | 16 | 56278792 |
Sinusitis | 22.80 | 17.04 | 9 | 13250 | 197572 | 56081236 |
Wound | 22.56 | 17.04 | 3 | 13256 | 138801 | 56140007 |
Laparoscopy | 22.45 | 17.04 | 5 | 13254 | 83 | 56278725 |
Hypotension | 22.19 | 17.04 | 16 | 13243 | 250492 | 56028316 |
Blood oestrogen increased | 22.18 | 17.04 | 5 | 13254 | 88 | 56278720 |
Bone pain | 21.85 | 17.04 | 41 | 13218 | 50144 | 56228664 |
Injection site erythema | 21.82 | 17.04 | 53 | 13206 | 77395 | 56201413 |
Urinary tract infection | 21.78 | 17.04 | 15 | 13244 | 240498 | 56038310 |
Infection | 21.70 | 17.04 | 10 | 13249 | 200196 | 56078612 |
Idiopathic intracranial hypertension | 21.57 | 17.04 | 11 | 13248 | 2543 | 56276265 |
Oophorectomy | 21.38 | 17.04 | 7 | 13252 | 518 | 56278290 |
Nasopharyngitis | 21.07 | 17.04 | 13 | 13246 | 220946 | 56057862 |
Intercepted product administration error | 20.67 | 17.04 | 5 | 13254 | 121 | 56278687 |
Expired product administered | 20.39 | 17.04 | 14 | 13245 | 5588 | 56273220 |
Amnesia | 20.36 | 17.04 | 38 | 13221 | 46284 | 56232524 |
Wrong product administered | 20.23 | 17.04 | 14 | 13245 | 5658 | 56273150 |
Drug hypersensitivity | 20.23 | 17.04 | 21 | 13238 | 275184 | 56003624 |
Confusional state | 20.19 | 17.04 | 12 | 13247 | 208143 | 56070665 |
Blood follicle stimulating hormone increased | 19.54 | 17.04 | 5 | 13254 | 153 | 56278655 |
Ovarian disorder | 19.48 | 17.04 | 7 | 13252 | 686 | 56278122 |
Autoimmune dermatitis | 19.41 | 17.04 | 4 | 13255 | 45 | 56278763 |
Completed suicide | 19.29 | 17.04 | 4 | 13255 | 133829 | 56144979 |
Libido decreased | 19.27 | 17.04 | 10 | 13249 | 2398 | 56276410 |
Product administration error | 18.93 | 17.04 | 24 | 13235 | 20905 | 56257903 |
Arthropathy | 18.79 | 17.04 | 12 | 13247 | 200263 | 56078545 |
Haematocolpos | 18.66 | 17.04 | 4 | 13255 | 55 | 56278753 |
Mood altered | 18.33 | 17.04 | 19 | 13240 | 13336 | 56265472 |
Malignant neoplasm progression | 18.26 | 17.04 | 48 | 13211 | 73539 | 56205269 |
Diarrhoea | 18.23 | 17.04 | 83 | 13176 | 638424 | 55640384 |
Oestrogen receptor assay positive | 18.02 | 17.04 | 6 | 13253 | 468 | 56278340 |
Inner ear disorder | 17.98 | 17.04 | 6 | 13253 | 471 | 56278337 |
Blood oestrogen abnormal | 17.91 | 17.04 | 3 | 13256 | 9 | 56278799 |
Placenta accreta | 17.90 | 17.04 | 5 | 13254 | 215 | 56278593 |
Abdominal distension | 17.62 | 17.04 | 49 | 13210 | 77577 | 56201231 |
Pelvic venous thrombosis | 17.57 | 17.04 | 8 | 13251 | 1443 | 56277365 |
Uterine pain | 17.33 | 17.04 | 5 | 13254 | 242 | 56278566 |
Blood oestrogen decreased | 17.29 | 17.04 | 5 | 13254 | 244 | 56278564 |
Menopausal symptoms | 17.27 | 17.04 | 9 | 13250 | 2176 | 56276632 |
Ovarian adhesion | 17.24 | 17.04 | 3 | 13256 | 12 | 56278796 |
Device issue | 17.22 | 17.04 | 23 | 13236 | 21083 | 56257725 |
Metastases to bone | 17.06 | 17.04 | 22 | 13237 | 19486 | 56259322 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Intercepted product preparation error | 15063.90 | 14.24 | 2838 | 50476 | 326 | 31643704 |
Syringe issue | 13638.51 | 14.24 | 2802 | 50512 | 2054 | 31641976 |
Device leakage | 9684.30 | 14.24 | 2156 | 51158 | 3257 | 31640773 |
Wrong technique in product usage process | 4867.46 | 14.24 | 1896 | 51418 | 31447 | 31612583 |
Prostatic specific antigen increased | 2365.62 | 14.24 | 880 | 52434 | 12658 | 31631372 |
Hot flush | 2282.33 | 14.24 | 900 | 52414 | 15296 | 31628734 |
Product physical consistency issue | 1761.04 | 14.24 | 349 | 52965 | 145 | 31643885 |
Prostate cancer | 1360.06 | 14.24 | 824 | 52490 | 36777 | 31607253 |
Prostate cancer metastatic | 884.40 | 14.24 | 345 | 52969 | 5659 | 31638371 |
Intercepted medication error | 832.82 | 14.24 | 188 | 53126 | 305 | 31643725 |
Death | 797.26 | 14.24 | 1817 | 51497 | 358752 | 31285278 |
Blood testosterone abnormal | 739.62 | 14.24 | 161 | 53153 | 197 | 31643833 |
Blood testosterone increased | 672.28 | 14.24 | 184 | 53130 | 870 | 31643160 |
Intercepted product administration error | 522.59 | 14.24 | 104 | 53210 | 46 | 31643984 |
Needle issue | 476.51 | 14.24 | 214 | 53100 | 5059 | 31638971 |
Metastases to bone | 446.89 | 14.24 | 259 | 53055 | 10589 | 31633441 |
Product leakage | 396.57 | 14.24 | 102 | 53212 | 359 | 31643671 |
Prostatic specific antigen abnormal | 390.39 | 14.24 | 102 | 53212 | 388 | 31643642 |
Osteonecrosis of jaw | 335.48 | 14.24 | 257 | 53057 | 16814 | 31627216 |
Hormone-refractory prostate cancer | 289.23 | 14.24 | 108 | 53206 | 1559 | 31642471 |
Product preparation error | 282.88 | 14.24 | 109 | 53205 | 1723 | 31642307 |
Product administration error | 259.65 | 14.24 | 211 | 53103 | 15036 | 31628994 |
Malignant neoplasm progression | 235.21 | 14.24 | 452 | 52862 | 78546 | 31565484 |
Injection site pain | 232.62 | 14.24 | 289 | 53025 | 34345 | 31609685 |
Terminal state | 220.99 | 14.24 | 113 | 53201 | 3585 | 31640445 |
Toxicity to various agents | 206.37 | 14.24 | 30 | 53284 | 181457 | 31462573 |
Injection site mass | 167.66 | 14.24 | 111 | 53203 | 5753 | 31638277 |
Marasmus | 161.13 | 14.24 | 52 | 53262 | 470 | 31643560 |
Prostate cancer recurrent | 158.93 | 14.24 | 60 | 53254 | 894 | 31643136 |
Fatigue | 151.09 | 14.24 | 1021 | 52293 | 334185 | 31309845 |
Incorrect route of product administration | 148.92 | 14.24 | 137 | 53177 | 11536 | 31632494 |
Intercepted product storage error | 135.13 | 14.24 | 37 | 53277 | 175 | 31643855 |
Circumstance or information capable of leading to medication error | 125.78 | 14.24 | 59 | 53255 | 1544 | 31642486 |
Injection site induration | 119.15 | 14.24 | 67 | 53247 | 2580 | 31641450 |
Completed suicide | 106.54 | 14.24 | 14 | 53300 | 91500 | 31552530 |
Acute kidney injury | 104.44 | 14.24 | 195 | 53119 | 279519 | 31364511 |
Injection site haemorrhage | 97.61 | 14.24 | 97 | 53217 | 8988 | 31635042 |
Metastases to lymph nodes | 96.63 | 14.24 | 70 | 53244 | 4198 | 31639832 |
Palliative care | 93.10 | 14.24 | 34 | 53280 | 459 | 31643571 |
Injection site granuloma | 92.61 | 14.24 | 18 | 53296 | 5 | 31644025 |
Drug interaction | 86.34 | 14.24 | 136 | 53178 | 208407 | 31435623 |
Underdose | 84.24 | 14.24 | 105 | 53209 | 12502 | 31631528 |
Diarrhoea | 83.87 | 14.24 | 308 | 53006 | 352101 | 31291929 |
Pyrexia | 81.51 | 14.24 | 252 | 53062 | 303588 | 31340442 |
Hydronephrosis | 79.23 | 14.24 | 88 | 53226 | 9273 | 31634757 |
Injection site abscess | 79.01 | 14.24 | 34 | 53280 | 722 | 31643308 |
Hypotension | 76.84 | 14.24 | 142 | 53172 | 204476 | 31439554 |
Overdose | 74.04 | 14.24 | 25 | 53289 | 84639 | 31559391 |
Bulbospinal muscular atrophy congenital | 72.61 | 14.24 | 15 | 53299 | 11 | 31644019 |
Extra dose administered | 70.75 | 14.24 | 53 | 53261 | 3347 | 31640683 |
Injection site necrosis | 70.47 | 14.24 | 26 | 53288 | 362 | 31643668 |
Device connection issue | 69.59 | 14.24 | 25 | 53289 | 321 | 31643709 |
Expired product administered | 68.83 | 14.24 | 50 | 53264 | 3011 | 31641019 |
Pelvic mass | 68.55 | 14.24 | 22 | 53292 | 195 | 31643835 |
Victim of child abuse | 66.76 | 14.24 | 32 | 53282 | 880 | 31643150 |
Cough | 65.72 | 14.24 | 78 | 53236 | 134736 | 31509294 |
Drug hypersensitivity | 62.50 | 14.24 | 22 | 53292 | 72577 | 31571453 |
Injection site nodule | 61.91 | 14.24 | 36 | 53278 | 1478 | 31642552 |
Bone pain | 61.51 | 14.24 | 114 | 53200 | 19237 | 31624793 |
Neutropenia | 61.45 | 14.24 | 88 | 53226 | 140276 | 31503754 |
Occupational exposure to product | 60.83 | 14.24 | 23 | 53291 | 344 | 31643686 |
Product reconstitution quality issue | 60.04 | 14.24 | 17 | 53297 | 93 | 31643937 |
Fall | 57.89 | 14.24 | 521 | 52793 | 185568 | 31458462 |
Psoriasis | 57.20 | 14.24 | 6 | 53308 | 46713 | 31597317 |
Injection site ulcer | 57.05 | 14.24 | 20 | 53294 | 238 | 31643792 |
Vomiting | 54.96 | 14.24 | 193 | 53121 | 223780 | 31420250 |
Intentional dose omission | 54.60 | 14.24 | 42 | 53272 | 2760 | 31641270 |
Drug administered in wrong device | 54.56 | 14.24 | 13 | 53301 | 30 | 31644000 |
Rheumatoid arthritis | 54.00 | 14.24 | 8 | 53306 | 47801 | 31596229 |
Intercepted product prescribing error | 53.91 | 14.24 | 16 | 53298 | 106 | 31643924 |
Foetal exposure during pregnancy | 53.42 | 14.24 | 4 | 53310 | 40872 | 31603158 |
Cystitis radiation | 52.83 | 14.24 | 15 | 53299 | 83 | 31643947 |
Interstitial lung disease | 52.07 | 14.24 | 223 | 53091 | 61180 | 31582850 |
Blood creatinine increased | 52.02 | 14.24 | 44 | 53270 | 89034 | 31554996 |
Pneumonia | 49.88 | 14.24 | 345 | 52969 | 334967 | 31309063 |
Dyspnoea | 49.83 | 14.24 | 356 | 52958 | 343123 | 31300907 |
Asthma | 48.43 | 14.24 | 7 | 53307 | 42604 | 31601426 |
Suicide attempt | 47.68 | 14.24 | 4 | 53310 | 37244 | 31606786 |
Urinary tract toxicity | 47.49 | 14.24 | 10 | 53304 | 9 | 31644021 |
Drug abuse | 46.92 | 14.24 | 47 | 53267 | 87711 | 31556319 |
Product colour issue | 46.46 | 14.24 | 20 | 53294 | 425 | 31643605 |
Infection | 45.99 | 14.24 | 42 | 53272 | 81889 | 31562141 |
Radiation proctitis | 45.19 | 14.24 | 13 | 53301 | 76 | 31643954 |
Metastasis | 45.17 | 14.24 | 42 | 53272 | 3582 | 31640448 |
Blood urea abnormal | 44.41 | 14.24 | 23 | 53291 | 749 | 31643281 |
Intercepted product selection error | 44.37 | 14.24 | 10 | 53304 | 16 | 31644014 |
White blood cell count decreased | 44.26 | 14.24 | 49 | 53265 | 87349 | 31556681 |
Gynaecomastia | 44.04 | 14.24 | 65 | 53249 | 9089 | 31634941 |
Metastases to lung | 43.72 | 14.24 | 62 | 53252 | 8360 | 31635670 |
Rash | 43.36 | 14.24 | 183 | 53131 | 201303 | 31442727 |
Off label use | 43.34 | 14.24 | 375 | 52939 | 346899 | 31297131 |
Injection site erythema | 43.23 | 14.24 | 83 | 53231 | 14379 | 31629651 |
Condition aggravated | 43.15 | 14.24 | 137 | 53177 | 163872 | 31480158 |
Metastatic salivary gland cancer | 43.12 | 14.24 | 8 | 53306 | 0 | 31644030 |
Cardiac arrest | 42.87 | 14.24 | 52 | 53262 | 89010 | 31555020 |
Agitation | 42.37 | 14.24 | 19 | 53295 | 54150 | 31589880 |
Reproductive toxicity | 42.28 | 14.24 | 9 | 53305 | 9 | 31644021 |
Product preparation issue | 42.13 | 14.24 | 17 | 53297 | 305 | 31643725 |
Renal impairment | 42.01 | 14.24 | 50 | 53264 | 86299 | 31557731 |
Angioedema | 41.98 | 14.24 | 4 | 53310 | 33614 | 31610416 |
Abdominal pain | 41.94 | 14.24 | 117 | 53197 | 145835 | 31498195 |
Febrile neutropenia | 41.84 | 14.24 | 89 | 53225 | 121760 | 31522270 |
Seizure | 41.26 | 14.24 | 65 | 53249 | 99703 | 31544327 |
Plasma cell myeloma | 40.93 | 14.24 | 22 | 53292 | 56509 | 31587521 |
Somnolence | 39.99 | 14.24 | 66 | 53248 | 99379 | 31544651 |
Bone lesion | 39.84 | 14.24 | 35 | 53279 | 2772 | 31641258 |
Nocturia | 39.37 | 14.24 | 62 | 53252 | 9173 | 31634857 |
Nausea | 39.08 | 14.24 | 331 | 52983 | 307616 | 31336414 |
Stress urinary incontinence | 38.80 | 14.24 | 12 | 53302 | 93 | 31643937 |
Male sexual dysfunction | 38.30 | 14.24 | 15 | 53299 | 248 | 31643782 |
Colon cancer stage III | 38.00 | 14.24 | 14 | 53300 | 194 | 31643836 |
Sepsis | 37.83 | 14.24 | 130 | 53184 | 151799 | 31492231 |
Cancer pain | 36.79 | 14.24 | 32 | 53282 | 2501 | 31641529 |
Tachycardia | 36.14 | 14.24 | 45 | 53269 | 76162 | 31567868 |
Prostatic specific antigen decreased | 36.10 | 14.24 | 12 | 53302 | 120 | 31643910 |
Incorrect dose administered | 36.00 | 14.24 | 137 | 53177 | 35615 | 31608415 |
Infusion related reaction | 35.83 | 14.24 | 18 | 53296 | 48037 | 31595993 |
Metabolic acidosis | 35.79 | 14.24 | 11 | 53303 | 39566 | 31604464 |
Blood electrolytes abnormal | 35.45 | 14.24 | 21 | 53293 | 893 | 31643137 |
Injection site swelling | 35.33 | 14.24 | 62 | 53252 | 10025 | 31634005 |
Back pain | 35.31 | 14.24 | 309 | 53005 | 109104 | 31534926 |
International normalised ratio increased | 35.15 | 14.24 | 16 | 53298 | 45207 | 31598823 |
Injection site inflammation | 34.77 | 14.24 | 19 | 53295 | 691 | 31643339 |
Coma | 34.50 | 14.24 | 13 | 53301 | 41137 | 31602893 |
Malignant transformation | 34.49 | 14.24 | 20 | 53294 | 817 | 31643213 |
Pancreatitis | 34.09 | 14.24 | 9 | 53305 | 35762 | 31608268 |
C-reactive protein increased | 33.69 | 14.24 | 20 | 53294 | 48630 | 31595400 |
Sinusitis | 33.55 | 14.24 | 10 | 53304 | 36686 | 31607344 |
Abscess sterile | 33.13 | 14.24 | 8 | 53306 | 20 | 31644010 |
Epidural lipomatosis | 33.01 | 14.24 | 19 | 53295 | 765 | 31643265 |
Platelet count decreased | 32.85 | 14.24 | 87 | 53227 | 110348 | 31533682 |
Urticaria | 32.85 | 14.24 | 29 | 53285 | 57488 | 31586542 |
Renal failure | 32.43 | 14.24 | 103 | 53211 | 123227 | 31520803 |
Anti-androgen withdrawal syndrome | 32.41 | 14.24 | 7 | 53307 | 8 | 31644022 |
Injection site abscess sterile | 32.34 | 14.24 | 6 | 53308 | 0 | 31644030 |
Gastrointestinal haemorrhage | 32.06 | 14.24 | 56 | 53258 | 82493 | 31561537 |
Pituitary haemorrhage | 31.77 | 14.24 | 12 | 53302 | 179 | 31643851 |
Hip fracture | 31.55 | 14.24 | 62 | 53252 | 10924 | 31633106 |
Metastases to spine | 31.51 | 14.24 | 28 | 53286 | 2252 | 31641778 |
Septic shock | 31.44 | 14.24 | 39 | 53275 | 66119 | 31577911 |
Product prescribing error | 31.28 | 14.24 | 88 | 53226 | 19554 | 31624476 |
Product dosage form issue | 30.91 | 14.24 | 8 | 53306 | 29 | 31644001 |
Asthenia | 30.48 | 14.24 | 539 | 52775 | 224216 | 31419814 |
Mucosal inflammation | 30.37 | 14.24 | 10 | 53304 | 34417 | 31609613 |
Pruritus | 29.87 | 14.24 | 109 | 53205 | 125058 | 31518972 |
Product storage error | 29.52 | 14.24 | 47 | 53267 | 7019 | 31637011 |
Blood creatine phosphokinase increased | 29.42 | 14.24 | 17 | 53297 | 41957 | 31602073 |
Pollakiuria | 29.29 | 14.24 | 81 | 53233 | 17821 | 31626209 |
Bone cancer | 29.19 | 14.24 | 22 | 53292 | 1402 | 31642628 |
Haematuria | 28.91 | 14.24 | 154 | 53160 | 46160 | 31597870 |
Thrombocytopenia | 28.64 | 14.24 | 133 | 53181 | 142614 | 31501416 |
Metastases to soft tissue | 28.50 | 14.24 | 12 | 53302 | 241 | 31643789 |
Bone cancer metastatic | 28.25 | 14.24 | 11 | 53303 | 179 | 31643851 |
Dementia | 27.65 | 14.24 | 63 | 53251 | 12297 | 31631733 |
Foreign body reaction | 27.63 | 14.24 | 8 | 53306 | 48 | 31643982 |
Urinary retention | 27.43 | 14.24 | 121 | 53193 | 33604 | 31610426 |
Haemoptysis | 27.27 | 14.24 | 10 | 53304 | 32179 | 31611851 |
Cardiogenic shock | 27.11 | 14.24 | 3 | 53311 | 22405 | 31621625 |
Product packaging quantity issue | 27.10 | 14.24 | 17 | 53297 | 802 | 31643228 |
Bradycardia | 26.95 | 14.24 | 47 | 53267 | 69280 | 31574750 |
Blood pressure increased | 26.62 | 14.24 | 59 | 53255 | 79574 | 31564456 |
Pancytopenia | 26.56 | 14.24 | 68 | 53246 | 87248 | 31556782 |
Fracture | 26.55 | 14.24 | 42 | 53272 | 6238 | 31637792 |
Chest pain | 26.51 | 14.24 | 104 | 53210 | 116853 | 31527177 |
Product quality issue | 26.46 | 14.24 | 73 | 53241 | 16038 | 31627992 |
Hypersensitivity | 26.33 | 14.24 | 33 | 53281 | 55710 | 31588320 |
Tremor | 26.06 | 14.24 | 56 | 53258 | 76364 | 31567666 |
Drug reaction with eosinophilia and systemic symptoms | 25.99 | 14.24 | 9 | 53305 | 30009 | 31614021 |
Chest discomfort | 25.73 | 14.24 | 27 | 53287 | 49342 | 31594688 |
Intercepted product dispensing error | 25.65 | 14.24 | 8 | 53306 | 64 | 31643966 |
Oxygen saturation decreased | 25.45 | 14.24 | 27 | 53287 | 49088 | 31594942 |
Induration | 25.36 | 14.24 | 17 | 53297 | 899 | 31643131 |
Urinary tract obstruction | 24.95 | 14.24 | 30 | 53284 | 3441 | 31640589 |
Injection site discomfort | 24.93 | 14.24 | 20 | 53294 | 1397 | 31642633 |
Product dispensing error | 24.79 | 14.24 | 39 | 53275 | 5765 | 31638265 |
Femur fracture | 24.71 | 14.24 | 45 | 53269 | 7488 | 31636542 |
Hyperkalaemia | 24.67 | 14.24 | 44 | 53270 | 64307 | 31579723 |
Intentional product use issue | 24.60 | 14.24 | 28 | 53286 | 49319 | 31594711 |
Macroenzyme creatine kinase | 24.57 | 14.24 | 6 | 53308 | 16 | 31644014 |
Respiratory distress | 24.37 | 14.24 | 13 | 53301 | 33540 | 31610490 |
White blood cell count increased | 24.34 | 14.24 | 18 | 53296 | 38982 | 31605048 |
Spinal compression fracture | 24.03 | 14.24 | 41 | 53273 | 6481 | 31637549 |
Child abuse | 23.98 | 14.24 | 12 | 53302 | 363 | 31643667 |
Respiratory failure | 23.77 | 14.24 | 89 | 53225 | 101360 | 31542670 |
Drug level increased | 23.68 | 14.24 | 3 | 53311 | 20183 | 31623847 |
Bladder neck obstruction | 23.60 | 14.24 | 9 | 53305 | 138 | 31643892 |
Leukopenia | 23.58 | 14.24 | 38 | 53276 | 57790 | 31586240 |
Nasopharyngitis | 23.57 | 14.24 | 44 | 53270 | 63201 | 31580829 |
Neutrophil count decreased | 23.48 | 14.24 | 26 | 53288 | 46368 | 31597662 |
Radical prostatectomy | 23.25 | 14.24 | 7 | 53307 | 49 | 31643981 |
Agranulocytosis | 22.99 | 14.24 | 4 | 53310 | 21243 | 31622787 |
Loss of libido | 22.87 | 14.24 | 24 | 53290 | 2371 | 31641659 |
Inappropriate schedule of product administration | 22.77 | 14.24 | 155 | 53159 | 50668 | 31593362 |
Respiratory arrest | 22.51 | 14.24 | 8 | 53306 | 26249 | 31617781 |
Testicular atrophy | 22.42 | 14.24 | 13 | 53301 | 531 | 31643499 |
Liver function test abnormal | 22.31 | 14.24 | 11 | 53303 | 29681 | 31614349 |
Product physical issue | 22.25 | 14.24 | 23 | 53291 | 2232 | 31641798 |
Hypoglycaemia | 22.20 | 14.24 | 32 | 53282 | 50914 | 31593116 |
Hepatic enzyme increased | 21.86 | 14.24 | 17 | 53297 | 35891 | 31608139 |
Multiple organ dysfunction syndrome | 21.61 | 14.24 | 52 | 53262 | 68151 | 31575879 |
Antiandrogen therapy | 21.56 | 14.24 | 4 | 53310 | 0 | 31644030 |
Breast tenderness | 21.36 | 14.24 | 14 | 53300 | 713 | 31643317 |
Anxiety | 21.23 | 14.24 | 80 | 53234 | 90953 | 31553077 |
Disease progression | 21.15 | 14.24 | 239 | 53075 | 90225 | 31553805 |
Aggression | 21.05 | 14.24 | 19 | 53295 | 37272 | 31606758 |
Headache | 20.78 | 14.24 | 203 | 53111 | 183449 | 31460581 |
Lower respiratory tract infection | 20.42 | 14.24 | 11 | 53303 | 28226 | 31615804 |
Injection site infection | 20.18 | 14.24 | 15 | 53299 | 936 | 31643094 |
Pancreatitis acute | 19.98 | 14.24 | 9 | 53305 | 25591 | 31618439 |
Radiotherapy | 19.96 | 14.24 | 11 | 53303 | 407 | 31643623 |
Rib fracture | 19.60 | 14.24 | 58 | 53256 | 13258 | 31630772 |
Juvenile idiopathic arthritis | 19.54 | 14.24 | 19 | 53295 | 1714 | 31642316 |
Bone density decreased | 19.52 | 14.24 | 19 | 53295 | 1716 | 31642314 |
Mental status changes | 19.51 | 14.24 | 19 | 53295 | 35949 | 31608081 |
Meningioma | 19.42 | 14.24 | 17 | 53297 | 1340 | 31642690 |
Colitis ulcerative | 18.96 | 14.24 | 4 | 53310 | 18525 | 31625505 |
Coagulopathy | 18.94 | 14.24 | 4 | 53310 | 18511 | 31625519 |
Dysuria | 18.88 | 14.24 | 86 | 53228 | 24208 | 31619822 |
Injection site discharge | 18.87 | 14.24 | 7 | 53307 | 99 | 31643931 |
Product size issue | 18.54 | 14.24 | 12 | 53302 | 598 | 31643432 |
Eosinophilia | 18.42 | 14.24 | 8 | 53306 | 23245 | 31620785 |
Product administered at inappropriate site | 18.41 | 14.24 | 19 | 53295 | 1841 | 31642189 |
Premature baby | 18.28 | 14.24 | 4 | 53310 | 18062 | 31625968 |
Lymphocyte count decreased | 18.20 | 14.24 | 6 | 53308 | 20643 | 31623387 |
Bronchitis | 18.20 | 14.24 | 23 | 53291 | 38694 | 31605336 |
Neuroendocrine carcinoma of prostate | 17.90 | 14.24 | 4 | 53310 | 6 | 31644024 |
Hypoxia | 17.88 | 14.24 | 36 | 53278 | 50277 | 31593753 |
Eye haematoma | 17.88 | 14.24 | 6 | 53308 | 62 | 31643968 |
Abdominal pain upper | 17.84 | 14.24 | 52 | 53262 | 63950 | 31580080 |
Encephalopathy | 17.79 | 14.24 | 17 | 53297 | 32457 | 31611573 |
Blood pressure fluctuation | 17.73 | 14.24 | 8 | 53306 | 22728 | 31621302 |
Small cell carcinoma | 17.54 | 14.24 | 7 | 53307 | 122 | 31643908 |
Metastases to breast | 17.52 | 14.24 | 4 | 53310 | 7 | 31644023 |
Blood glucose increased | 17.49 | 14.24 | 49 | 53265 | 61034 | 31582996 |
Injection site reaction | 17.39 | 14.24 | 51 | 53263 | 11600 | 31632430 |
Metastases to liver | 17.38 | 14.24 | 54 | 53260 | 12673 | 31631357 |
Haematochezia | 17.06 | 14.24 | 26 | 53288 | 40438 | 31603592 |
Therapy non-responder | 17.05 | 14.24 | 19 | 53295 | 33792 | 31610238 |
Transitional cell carcinoma | 16.81 | 14.24 | 19 | 53295 | 2040 | 31641990 |
Lipid metabolism disorder | 16.78 | 14.24 | 9 | 53305 | 315 | 31643715 |
Product use in unapproved indication | 16.73 | 14.24 | 98 | 53216 | 99073 | 31544957 |
Muscular weakness | 16.71 | 14.24 | 176 | 53138 | 65272 | 31578758 |
Traumatic fracture | 16.68 | 14.24 | 9 | 53305 | 319 | 31643711 |
Ascites | 16.67 | 14.24 | 27 | 53287 | 40986 | 31603044 |
Respiratory depression | 16.62 | 14.24 | 58 | 53256 | 14452 | 31629578 |
Pituitary apoplexy | 16.37 | 14.24 | 5 | 53309 | 37 | 31643993 |
Diabetes mellitus | 16.30 | 14.24 | 125 | 53189 | 42431 | 31601599 |
Urethral intrinsic sphincter deficiency | 16.29 | 14.24 | 4 | 53310 | 11 | 31644019 |
Injection site extravasation | 16.26 | 14.24 | 21 | 53293 | 2589 | 31641441 |
Product availability issue | 16.25 | 14.24 | 16 | 53298 | 1465 | 31642565 |
Anaplastic meningioma | 16.17 | 14.24 | 3 | 53311 | 0 | 31644030 |
Blood testosterone normal | 16.17 | 14.24 | 3 | 53311 | 0 | 31644030 |
Prostatic specific antigen | 16.17 | 14.24 | 3 | 53311 | 0 | 31644030 |
Metastases to penis | 16.17 | 14.24 | 3 | 53311 | 0 | 31644030 |
Shock | 16.11 | 14.24 | 9 | 53305 | 22636 | 31621394 |
Pelvic pain | 16.06 | 14.24 | 19 | 53295 | 2142 | 31641888 |
Erythema | 16.06 | 14.24 | 75 | 53239 | 80330 | 31563700 |
Lactic acidosis | 16.05 | 14.24 | 18 | 53296 | 31919 | 31612111 |
Metastases to spinal cord | 16.03 | 14.24 | 4 | 53310 | 12 | 31644018 |
Stomatitis | 16.00 | 14.24 | 26 | 53288 | 39412 | 31604618 |
Haemorrhage | 15.87 | 14.24 | 35 | 53279 | 47299 | 31596731 |
Urine flow decreased | 15.83 | 14.24 | 14 | 53300 | 1119 | 31642911 |
Ectopic ACTH syndrome | 15.79 | 14.24 | 4 | 53310 | 13 | 31644017 |
Vipoma | 15.79 | 14.24 | 4 | 53310 | 13 | 31644017 |
Psychotic disorder | 15.66 | 14.24 | 9 | 53305 | 22284 | 31621746 |
Neurotoxicity | 15.62 | 14.24 | 4 | 53310 | 16222 | 31627808 |
Anaphylactic reaction | 15.58 | 14.24 | 16 | 53298 | 29537 | 31614493 |
Therapeutic response decreased | 15.57 | 14.24 | 13 | 53301 | 26496 | 31617534 |
Eye colour change | 15.46 | 14.24 | 8 | 53306 | 260 | 31643770 |
Heart rate decreased | 15.25 | 14.24 | 15 | 53299 | 28251 | 31615779 |
Skin exfoliation | 14.92 | 14.24 | 11 | 53303 | 23863 | 31620167 |
Hypervolaemia | 14.91 | 14.24 | 6 | 53308 | 18245 | 31625785 |
Erectile dysfunction | 14.88 | 14.24 | 68 | 53246 | 19167 | 31624863 |
Second primary malignancy | 14.81 | 14.24 | 35 | 53279 | 6997 | 31637033 |
Diabetic ketoacidosis | 14.75 | 14.24 | 5 | 53309 | 16900 | 31627130 |
Blood testosterone decreased | 14.62 | 14.24 | 26 | 53288 | 4247 | 31639783 |
Staphylococcal infection | 14.60 | 14.24 | 18 | 53296 | 30614 | 31613416 |
Wrong device used | 14.59 | 14.24 | 4 | 53310 | 19 | 31644011 |
Bone marrow tumour cell infiltration | 14.59 | 14.24 | 4 | 53310 | 19 | 31644011 |
Product use issue | 14.48 | 14.24 | 48 | 53266 | 56711 | 31587319 |
Joint swelling | 14.47 | 14.24 | 44 | 53270 | 53387 | 31590643 |
Enzyme induction | 14.46 | 14.24 | 5 | 53309 | 57 | 31643973 |
Culture positive | 14.42 | 14.24 | 11 | 53303 | 714 | 31643316 |
Tumour lysis syndrome | 14.41 | 14.24 | 4 | 53310 | 15381 | 31628649 |
Urethral obstruction | 14.38 | 14.24 | 5 | 53309 | 58 | 31643972 |
Wheezing | 14.34 | 14.24 | 24 | 53290 | 35962 | 31608068 |
Pleural effusion | 14.31 | 14.24 | 71 | 53243 | 74849 | 31569181 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Intercepted product preparation error | 12103.15 | 13.03 | 2008 | 46867 | 634 | 70878935 |
Syringe issue | 10652.02 | 13.03 | 2001 | 46874 | 3327 | 70876242 |
Device leakage | 7119.40 | 13.03 | 1574 | 47301 | 7734 | 70871835 |
Wrong technique in product usage process | 3174.07 | 13.03 | 1331 | 47544 | 67367 | 70812202 |
Prostatic specific antigen increased | 2296.60 | 13.03 | 638 | 48237 | 8828 | 70870741 |
Hot flush | 1495.21 | 13.03 | 714 | 48161 | 48870 | 70830699 |
Product physical consistency issue | 1317.71 | 13.03 | 250 | 48625 | 439 | 70879130 |
Prostate cancer | 1170.87 | 13.03 | 523 | 48352 | 30640 | 70848929 |
Intercepted medication error | 639.52 | 13.03 | 143 | 48732 | 734 | 70878835 |
Prostate cancer metastatic | 576.69 | 13.03 | 180 | 48695 | 3789 | 70875780 |
Blood testosterone abnormal | 561.58 | 13.03 | 101 | 48774 | 107 | 70879462 |
Blood testosterone increased | 519.99 | 13.03 | 120 | 48755 | 726 | 70878843 |
Death | 441.33 | 13.03 | 1037 | 47838 | 509024 | 70370545 |
Intercepted product administration error | 394.68 | 13.03 | 76 | 48799 | 150 | 70879419 |
Metastases to bone | 323.19 | 13.03 | 198 | 48677 | 22178 | 70857391 |
Prostatic specific antigen abnormal | 305.37 | 13.03 | 63 | 48812 | 202 | 70879367 |
Needle issue | 303.67 | 13.03 | 149 | 48726 | 10766 | 70868803 |
Osteonecrosis of jaw | 300.03 | 13.03 | 239 | 48636 | 40763 | 70838806 |
Endometriosis | 256.27 | 13.03 | 93 | 48782 | 3143 | 70876426 |
Product leakage | 251.99 | 13.03 | 66 | 48809 | 715 | 70878854 |
Malignant neoplasm progression | 234.58 | 13.03 | 350 | 48525 | 121389 | 70758180 |
Hormone-refractory prostate cancer | 221.96 | 13.03 | 63 | 48812 | 941 | 70878628 |
Prostate cancer recurrent | 195.57 | 13.03 | 54 | 48821 | 725 | 70878844 |
Pelvic pain | 168.70 | 13.03 | 103 | 48772 | 11457 | 70868112 |
Toxicity to various agents | 166.58 | 13.03 | 31 | 48844 | 382141 | 70497428 |
Rheumatoid arthritis | 161.44 | 13.03 | 10 | 48865 | 291795 | 70587774 |
Injection site abscess | 154.68 | 13.03 | 52 | 48823 | 1394 | 70878175 |
Occupational exposure to product | 142.97 | 13.03 | 42 | 48833 | 713 | 70878856 |
Injection site pain | 137.54 | 13.03 | 271 | 48604 | 117348 | 70762221 |
Ovarian hyperstimulation syndrome | 133.19 | 13.03 | 58 | 48817 | 3182 | 70876387 |
Product preparation error | 129.83 | 13.03 | 63 | 48812 | 4439 | 70875130 |
Product administration error | 124.22 | 13.03 | 126 | 48749 | 29397 | 70850172 |
Abscess sterile | 117.62 | 13.03 | 23 | 48852 | 51 | 70879518 |
Intercepted product storage error | 106.00 | 13.03 | 26 | 48849 | 211 | 70879358 |
Completed suicide | 104.23 | 13.03 | 16 | 48859 | 227119 | 70652450 |
Injection site mass | 101.34 | 13.03 | 91 | 48784 | 18252 | 70861317 |
Victim of child abuse | 93.53 | 13.03 | 32 | 48843 | 906 | 70878663 |
Vaginal haemorrhage | 93.26 | 13.03 | 91 | 48784 | 20261 | 70859308 |
Hydronephrosis | 92.98 | 13.03 | 80 | 48795 | 15162 | 70864407 |
Drug hypersensitivity | 91.94 | 13.03 | 33 | 48842 | 262426 | 70617143 |
Injection site granuloma | 90.54 | 13.03 | 18 | 48857 | 45 | 70879524 |
Infusion related reaction | 77.90 | 13.03 | 20 | 48855 | 197514 | 70682055 |
Bulbospinal muscular atrophy congenital | 77.75 | 13.03 | 14 | 48861 | 15 | 70879554 |
Incorrect route of product administration | 76.73 | 13.03 | 93 | 48782 | 26399 | 70853170 |
Joint swelling | 74.29 | 13.03 | 41 | 48834 | 253170 | 70626399 |
Sinusitis | 73.02 | 13.03 | 14 | 48861 | 169181 | 70710388 |
Injection site haemorrhage | 72.94 | 13.03 | 89 | 48786 | 25438 | 70854131 |
Injection site induration | 70.36 | 13.03 | 55 | 48820 | 9113 | 70870456 |
Fatigue | 69.45 | 13.03 | 869 | 48006 | 823450 | 70056119 |
Marasmus | 67.30 | 13.03 | 25 | 48850 | 903 | 70878666 |
Cough | 66.21 | 13.03 | 76 | 48799 | 325301 | 70554268 |
Terminal state | 64.18 | 13.03 | 40 | 48835 | 4612 | 70874957 |
Nasopharyngitis | 63.70 | 13.03 | 37 | 48838 | 222169 | 70657400 |
Circumstance or information capable of leading to medication error | 62.89 | 13.03 | 36 | 48839 | 3554 | 70876015 |
Injection site abscess sterile | 62.52 | 13.03 | 11 | 48864 | 9 | 70879560 |
Cystitis radiation | 61.45 | 13.03 | 15 | 48860 | 119 | 70879450 |
Extra dose administered | 60.98 | 13.03 | 46 | 48829 | 7231 | 70872338 |
Infection | 60.56 | 13.03 | 35 | 48840 | 210750 | 70668819 |
Male sexual dysfunction | 59.74 | 13.03 | 16 | 48859 | 190 | 70879379 |
Gynaecomastia | 59.11 | 13.03 | 44 | 48831 | 6779 | 70872790 |
Uterine leiomyoma | 59.06 | 13.03 | 41 | 48834 | 5666 | 70873903 |
Pelvic mass | 58.94 | 13.03 | 24 | 48851 | 1112 | 70878457 |
Interstitial lung disease | 58.69 | 13.03 | 182 | 48693 | 104503 | 70775066 |
Heavy menstrual bleeding | 56.85 | 13.03 | 56 | 48819 | 12609 | 70866960 |
Overdose | 55.04 | 13.03 | 24 | 48851 | 169721 | 70709848 |
Hysterectomy | 55.01 | 13.03 | 39 | 48836 | 5573 | 70873996 |
Haematuria | 54.21 | 13.03 | 129 | 48746 | 63444 | 70816125 |
Lower respiratory tract infection | 53.37 | 13.03 | 7 | 48868 | 111906 | 70767663 |
Diarrhoea | 52.97 | 13.03 | 320 | 48555 | 783021 | 70096548 |
Drug administered in wrong device | 52.46 | 13.03 | 11 | 48864 | 39 | 70879530 |
Underdose | 51.59 | 13.03 | 81 | 48794 | 29302 | 70850267 |
Metastases to lymph nodes | 51.36 | 13.03 | 46 | 48829 | 9192 | 70870377 |
Product reconstitution quality issue | 51.26 | 13.03 | 14 | 48861 | 180 | 70879389 |
Drug intolerance | 51.21 | 13.03 | 48 | 48827 | 225639 | 70653930 |
Arthropathy | 50.61 | 13.03 | 20 | 48855 | 150037 | 70729532 |
Metastatic salivary gland cancer | 50.25 | 13.03 | 8 | 48867 | 0 | 70879569 |
Oestradiol increased | 49.87 | 13.03 | 12 | 48863 | 89 | 70879480 |
Blood urea abnormal | 49.77 | 13.03 | 22 | 48853 | 1251 | 70878318 |
Hepatic enzyme increased | 49.64 | 13.03 | 23 | 48852 | 156967 | 70722602 |
Maternal exposure during pregnancy | 48.80 | 13.03 | 10 | 48865 | 115335 | 70764234 |
Hypersensitivity | 48.57 | 13.03 | 52 | 48823 | 229760 | 70649809 |
Mood swings | 47.83 | 13.03 | 61 | 48814 | 18225 | 70861344 |
Rash | 47.55 | 13.03 | 186 | 48689 | 510376 | 70369193 |
Wound | 47.50 | 13.03 | 6 | 48869 | 98726 | 70780843 |
Condition aggravated | 46.37 | 13.03 | 146 | 48729 | 427489 | 70452080 |
Epidural lipomatosis | 45.52 | 13.03 | 19 | 48856 | 938 | 70878631 |
Malignant transformation | 44.98 | 13.03 | 20 | 48855 | 1153 | 70878416 |
Metastases to liver | 44.96 | 13.03 | 71 | 48804 | 25807 | 70853762 |
Systemic lupus erythematosus | 44.88 | 13.03 | 8 | 48867 | 101894 | 70777675 |
Metastases to lung | 44.72 | 13.03 | 56 | 48819 | 16428 | 70863141 |
Radiation proctitis | 44.55 | 13.03 | 11 | 48864 | 92 | 70879477 |
Asthma | 44.33 | 13.03 | 14 | 48861 | 120779 | 70758790 |
Epiphysiolysis | 44.13 | 13.03 | 11 | 48864 | 96 | 70879473 |
Swelling | 44.07 | 13.03 | 39 | 48836 | 188500 | 70691069 |
Hypotension | 43.18 | 13.03 | 139 | 48736 | 404242 | 70475327 |
Product prescribing error | 42.19 | 13.03 | 87 | 48788 | 38865 | 70840704 |
Therapeutic product effect decreased | 42.14 | 13.03 | 23 | 48852 | 142995 | 70736574 |
Disease progression | 41.88 | 13.03 | 216 | 48659 | 156456 | 70723113 |
Intentional dose omission | 41.46 | 13.03 | 36 | 48839 | 6905 | 70872664 |
Pericarditis | 41.11 | 13.03 | 5 | 48870 | 84700 | 70794869 |
Pituitary haemorrhage | 40.83 | 13.03 | 13 | 48862 | 292 | 70879277 |
Bone pain | 39.99 | 13.03 | 100 | 48775 | 50722 | 70828847 |
Expired product administered | 39.80 | 13.03 | 34 | 48841 | 6379 | 70873190 |
Device connection issue | 39.71 | 13.03 | 17 | 48858 | 894 | 70878675 |
Intercepted product selection error | 39.64 | 13.03 | 7 | 48868 | 6 | 70879563 |
Injection site nodule | 39.13 | 13.03 | 26 | 48849 | 3344 | 70876225 |
Anti-androgen withdrawal syndrome | 38.64 | 13.03 | 7 | 48868 | 8 | 70879561 |
Bone lesion | 38.30 | 13.03 | 31 | 48844 | 5399 | 70874170 |
Urinary tract obstruction | 37.88 | 13.03 | 28 | 48847 | 4269 | 70875300 |
Urinary retention | 37.87 | 13.03 | 100 | 48775 | 52420 | 70827149 |
Blood testosterone decreased | 37.35 | 13.03 | 22 | 48853 | 2291 | 70877278 |
Somnolence | 37.05 | 13.03 | 57 | 48818 | 215549 | 70664020 |
Psoriasis | 36.85 | 13.03 | 11 | 48864 | 98422 | 70781147 |
Blood luteinising hormone increased | 36.74 | 13.03 | 11 | 48864 | 200 | 70879369 |
Blood electrolytes abnormal | 36.71 | 13.03 | 20 | 48855 | 1794 | 70877775 |
Dyspnoea | 36.59 | 13.03 | 347 | 48528 | 769713 | 70109856 |
Product dosage form issue | 36.11 | 13.03 | 8 | 48867 | 39 | 70879530 |
Drug interaction | 36.09 | 13.03 | 138 | 48737 | 381303 | 70498266 |
Intentional product use issue | 35.86 | 13.03 | 19 | 48856 | 120123 | 70759446 |
Nocturia | 35.59 | 13.03 | 43 | 48832 | 12161 | 70867408 |
Metastasis | 35.09 | 13.03 | 31 | 48844 | 6083 | 70873486 |
Endometrial stromal sarcoma | 35.07 | 13.03 | 7 | 48868 | 18 | 70879551 |
Coma | 34.87 | 13.03 | 10 | 48865 | 91834 | 70787735 |
Child abuse | 34.38 | 13.03 | 12 | 48863 | 361 | 70879208 |
Injection site ulcer | 34.01 | 13.03 | 14 | 48861 | 667 | 70878902 |
Product quality issue | 33.97 | 13.03 | 69 | 48806 | 30492 | 70849077 |
Abdominal discomfort | 33.86 | 13.03 | 60 | 48815 | 214598 | 70664971 |
Product colour issue | 32.98 | 13.03 | 14 | 48861 | 721 | 70878848 |
Vomiting | 32.71 | 13.03 | 257 | 48618 | 592854 | 70286715 |
Diabetes mellitus | 32.34 | 13.03 | 116 | 48759 | 71708 | 70807861 |
Prostatic specific antigen decreased | 32.28 | 13.03 | 8 | 48867 | 68 | 70879501 |
Dysmenorrhoea | 32.19 | 13.03 | 21 | 48854 | 2619 | 70876950 |
Injury associated with device | 32.02 | 13.03 | 22 | 48853 | 2990 | 70876579 |
Bronchitis | 31.53 | 13.03 | 21 | 48854 | 117222 | 70762347 |
Intermenstrual bleeding | 30.89 | 13.03 | 27 | 48848 | 5223 | 70874346 |
Menstrual disorder | 30.79 | 13.03 | 23 | 48852 | 3563 | 70876006 |
Focal nodular hyperplasia | 30.51 | 13.03 | 13 | 48862 | 676 | 70878893 |
Erectile dysfunction | 30.47 | 13.03 | 42 | 48833 | 13520 | 70866049 |
Metastases to spine | 29.45 | 13.03 | 23 | 48852 | 3806 | 70875763 |
Bladder neck obstruction | 29.42 | 13.03 | 8 | 48867 | 101 | 70879468 |
Asthenia | 29.23 | 13.03 | 460 | 48415 | 457206 | 70422363 |
Lipid metabolism disorder | 28.61 | 13.03 | 10 | 48865 | 302 | 70879267 |
Loss of libido | 28.36 | 13.03 | 19 | 48856 | 2478 | 70877091 |
Pyrexia | 28.15 | 13.03 | 275 | 48600 | 606677 | 70272892 |
Back pain | 28.08 | 13.03 | 298 | 48577 | 270854 | 70608715 |
Intercepted product dispensing error | 27.22 | 13.03 | 8 | 48867 | 136 | 70879433 |
Neuroendocrine breast tumour | 26.96 | 13.03 | 6 | 48869 | 30 | 70879539 |
Dysuria | 26.94 | 13.03 | 81 | 48794 | 45713 | 70833856 |
Nausea | 26.73 | 13.03 | 420 | 48455 | 851668 | 70027901 |
Psoriatic arthropathy | 26.61 | 13.03 | 6 | 48869 | 64765 | 70814804 |
Meningioma | 26.37 | 13.03 | 22 | 48853 | 3996 | 70875573 |
Respiratory depression | 26.35 | 13.03 | 55 | 48820 | 24776 | 70854793 |
Incorrect dose administered | 26.09 | 13.03 | 103 | 48772 | 66616 | 70812953 |
Pruritus | 26.05 | 13.03 | 136 | 48739 | 345424 | 70534145 |
Palliative care | 26.05 | 13.03 | 12 | 48863 | 752 | 70878817 |
Acute kidney injury | 25.98 | 13.03 | 206 | 48669 | 474418 | 70405151 |
Intercepted product prescribing error | 25.50 | 13.03 | 9 | 48866 | 280 | 70879289 |
Pollakiuria | 25.44 | 13.03 | 65 | 48810 | 33396 | 70846173 |
Tachycardia | 25.28 | 13.03 | 44 | 48831 | 158502 | 70721067 |
Neuroendocrine carcinoma of prostate | 25.12 | 13.03 | 4 | 48871 | 0 | 70879569 |
Pituitary apoplexy | 25.07 | 13.03 | 8 | 48867 | 181 | 70879388 |
Stomatitis | 25.05 | 13.03 | 31 | 48844 | 128480 | 70751089 |
Metabolic acidosis | 24.91 | 13.03 | 10 | 48865 | 74336 | 70805233 |
Cancer pain | 24.61 | 13.03 | 23 | 48852 | 4851 | 70874718 |
Adnexa uteri pain | 24.60 | 13.03 | 9 | 48866 | 311 | 70879258 |
Macroenzyme creatine kinase | 24.48 | 13.03 | 5 | 48870 | 15 | 70879554 |
Angioedema | 23.94 | 13.03 | 8 | 48867 | 66602 | 70812967 |
International normalised ratio increased | 23.75 | 13.03 | 13 | 48862 | 80713 | 70798856 |
Dental fistula | 23.70 | 13.03 | 10 | 48865 | 507 | 70879062 |
Foreign body reaction | 23.04 | 13.03 | 7 | 48868 | 134 | 70879435 |
Oxygen saturation decreased | 22.78 | 13.03 | 28 | 48847 | 116401 | 70763168 |
Metastases to soft tissue | 22.54 | 13.03 | 9 | 48866 | 396 | 70879173 |
Leiomyosarcoma recurrent | 22.35 | 13.03 | 4 | 48871 | 4 | 70879565 |
Product dispensing error | 22.33 | 13.03 | 34 | 48841 | 11974 | 70867595 |
Injection site necrosis | 22.14 | 13.03 | 13 | 48862 | 1346 | 70878223 |
Transitional cell carcinoma | 22.11 | 13.03 | 16 | 48859 | 2361 | 70877208 |
Discomfort | 22.09 | 13.03 | 24 | 48851 | 105412 | 70774157 |
Gastrointestinal disorder | 22.09 | 13.03 | 24 | 48851 | 105403 | 70774166 |
Loss of personal independence in daily activities | 21.78 | 13.03 | 16 | 48859 | 84894 | 70794675 |
Pancreatitis | 21.71 | 13.03 | 8 | 48867 | 62660 | 70816909 |
Suicide attempt | 21.70 | 13.03 | 14 | 48861 | 79496 | 70800073 |
Blood pressure fluctuation | 21.36 | 13.03 | 7 | 48868 | 59005 | 70820564 |
Prosopagnosia | 21.16 | 13.03 | 5 | 48870 | 34 | 70879535 |
Adnexal torsion | 21 | 13.03 | 8 | 48867 | 310 | 70879259 |
Blister | 20.93 | 13.03 | 23 | 48852 | 100503 | 70779066 |
Night sweats | 20.91 | 13.03 | 72 | 48803 | 43612 | 70835957 |
Therapeutic product effect incomplete | 20.29 | 13.03 | 32 | 48843 | 119850 | 70759719 |
Renal impairment | 20.28 | 13.03 | 43 | 48832 | 143894 | 70735675 |
Injection site infection | 20.07 | 13.03 | 14 | 48861 | 1950 | 70877619 |
Testicular atrophy | 20.04 | 13.03 | 8 | 48867 | 352 | 70879217 |
Metastases to spinal cord | 19.92 | 13.03 | 5 | 48870 | 45 | 70879524 |
Urine flow decreased | 19.62 | 13.03 | 11 | 48864 | 1043 | 70878526 |
Spinal compression fracture | 19.57 | 13.03 | 37 | 48838 | 15516 | 70864053 |
Eye haematoma | 19.45 | 13.03 | 6 | 48869 | 121 | 70879448 |
Radical prostatectomy | 19.35 | 13.03 | 4 | 48871 | 13 | 70879556 |
Prostatic mass | 19.35 | 13.03 | 4 | 48871 | 13 | 70879556 |
Breast enlargement | 19.34 | 13.03 | 12 | 48863 | 1372 | 70878197 |
Drug dependence | 19.18 | 13.03 | 63 | 48812 | 37258 | 70842311 |
Tremor | 19.12 | 13.03 | 50 | 48825 | 155574 | 70723995 |
Drug reaction with eosinophilia and systemic symptoms | 19.12 | 13.03 | 8 | 48867 | 58005 | 70821564 |
Drug abuse | 19.11 | 13.03 | 46 | 48829 | 147210 | 70732359 |
Blood creatinine increased | 19.09 | 13.03 | 44 | 48831 | 142957 | 70736612 |
Pneumonia | 18.94 | 13.03 | 293 | 48582 | 595939 | 70283630 |
Ill-defined disorder | 18.94 | 13.03 | 7 | 48868 | 54734 | 70824835 |
Libido decreased | 18.90 | 13.03 | 20 | 48855 | 4896 | 70874673 |
Urethral intrinsic sphincter deficiency | 18.90 | 13.03 | 4 | 48871 | 15 | 70879554 |
Anaplastic meningioma | 18.84 | 13.03 | 3 | 48872 | 0 | 70879569 |
Blood testosterone normal | 18.84 | 13.03 | 3 | 48872 | 0 | 70879569 |
Product packaging quantity issue | 18.80 | 13.03 | 11 | 48864 | 1131 | 70878438 |
Vulvovaginal dryness | 18.75 | 13.03 | 13 | 48862 | 1793 | 70877776 |
Vipoma | 18.70 | 13.03 | 4 | 48871 | 16 | 70879553 |
Lactic acidosis | 18.37 | 13.03 | 11 | 48864 | 65013 | 70814556 |
Uterine haemorrhage | 18.25 | 13.03 | 15 | 48860 | 2669 | 70876900 |
Prostatic obstruction | 18.18 | 13.03 | 5 | 48870 | 66 | 70879503 |
Hypoglycaemia | 18.14 | 13.03 | 23 | 48852 | 94341 | 70785228 |
Product size issue | 18.04 | 13.03 | 9 | 48866 | 673 | 70878896 |
Therapy non-responder | 17.85 | 13.03 | 16 | 48859 | 76899 | 70802670 |
Hospice care | 17.82 | 13.03 | 25 | 48850 | 8180 | 70871389 |
Musculoskeletal stiffness | 17.75 | 13.03 | 48 | 48827 | 147712 | 70731857 |
Product preparation issue | 17.63 | 13.03 | 10 | 48865 | 970 | 70878599 |
Product storage error | 17.57 | 13.03 | 34 | 48841 | 14507 | 70865062 |
Pulmonary embolism | 17.40 | 13.03 | 174 | 48701 | 155693 | 70723876 |
Ovarian cyst | 17.35 | 13.03 | 30 | 48845 | 11742 | 70867827 |
Precocious puberty | 17.34 | 13.03 | 7 | 48868 | 317 | 70879252 |
Rib fracture | 16.99 | 13.03 | 47 | 48828 | 25309 | 70854260 |
Oropharyngeal pain | 16.98 | 13.03 | 25 | 48850 | 96285 | 70783284 |
Injection site inflammation | 16.93 | 13.03 | 16 | 48859 | 3422 | 70876147 |
Respiratory arrest | 16.89 | 13.03 | 8 | 48867 | 53925 | 70825644 |
Laparoscopy | 16.83 | 13.03 | 4 | 48871 | 28 | 70879541 |
Chest discomfort | 16.82 | 13.03 | 38 | 48837 | 124343 | 70755226 |
Irritable bowel syndrome | 16.77 | 13.03 | 7 | 48868 | 50843 | 70828726 |
Cardiac ventricular scarring | 16.77 | 13.03 | 3 | 48872 | 3 | 70879566 |
Arthritis | 16.72 | 13.03 | 26 | 48849 | 97954 | 70781615 |
Urticaria | 16.70 | 13.03 | 57 | 48818 | 162992 | 70716577 |
Blood pressure increased | 16.66 | 13.03 | 70 | 48805 | 188447 | 70691122 |
Inappropriate schedule of product administration | 16.64 | 13.03 | 129 | 48746 | 107426 | 70772143 |
Induration | 16.62 | 13.03 | 12 | 48863 | 1764 | 70877805 |
Lymphadenopathy | 16.47 | 13.03 | 72 | 48803 | 48719 | 70830850 |
Abdominal pain upper | 16.43 | 13.03 | 73 | 48802 | 193529 | 70686040 |
Bone cancer metastatic | 16.41 | 13.03 | 6 | 48869 | 207 | 70879362 |
Liver function test abnormal | 16.37 | 13.03 | 11 | 48864 | 61135 | 70818434 |
Blood follicle stimulating hormone abnormal | 16.30 | 13.03 | 3 | 48872 | 4 | 70879565 |
Injection site discomfort | 16.21 | 13.03 | 18 | 48857 | 4651 | 70874918 |
Juvenile idiopathic arthritis | 16.21 | 13.03 | 20 | 48855 | 5780 | 70873789 |
Prostate cancer stage IV | 16.21 | 13.03 | 13 | 48862 | 2235 | 70877334 |
Agranulocytosis | 16.02 | 13.03 | 4 | 48871 | 40294 | 70839275 |
Neuroendocrine carcinoma | 16.02 | 13.03 | 8 | 48867 | 600 | 70878969 |
Product physical issue | 15.89 | 13.03 | 16 | 48859 | 3698 | 70875871 |
Use of accessory respiratory muscles | 15.74 | 13.03 | 7 | 48868 | 404 | 70879165 |
Agitation | 15.73 | 13.03 | 25 | 48850 | 93350 | 70786219 |
Hypervolaemia | 15.68 | 13.03 | 4 | 48871 | 39702 | 70839867 |
Cardiogenic shock | 15.66 | 13.03 | 3 | 48872 | 36304 | 70843265 |
Cardiac arrest | 15.62 | 13.03 | 57 | 48818 | 159777 | 70719792 |
Septic shock | 15.42 | 13.03 | 34 | 48841 | 112224 | 70767345 |
Acute coronary syndrome | 15.26 | 13.03 | 39 | 48836 | 20040 | 70859529 |
Stress urinary incontinence | 14.93 | 13.03 | 11 | 48864 | 1669 | 70877900 |
Pathological fracture | 14.89 | 13.03 | 25 | 48850 | 9558 | 70870011 |
Haematocolpos | 14.82 | 13.03 | 4 | 48871 | 49 | 70879520 |
Bone marrow tumour cell infiltration | 14.82 | 13.03 | 4 | 48871 | 49 | 70879520 |
Erythema | 14.76 | 13.03 | 79 | 48796 | 199484 | 70680085 |
Oophorectomy | 14.75 | 13.03 | 6 | 48869 | 277 | 70879292 |
Urethral stenosis | 14.60 | 13.03 | 9 | 48866 | 1018 | 70878551 |
Inguinal hernia | 14.50 | 13.03 | 19 | 48856 | 5826 | 70873743 |
Respiratory distress | 14.41 | 13.03 | 10 | 48865 | 54640 | 70824929 |
Oncologic complication | 14.34 | 13.03 | 6 | 48869 | 298 | 70879271 |
Blood cholesterol increased | 14.33 | 13.03 | 14 | 48861 | 64590 | 70814979 |
Exposure during pregnancy | 14.29 | 13.03 | 24 | 48851 | 87693 | 70791876 |
Autoimmune dermatitis | 14.27 | 13.03 | 4 | 48871 | 57 | 70879512 |
Polyneuropathy in malignant disease | 14.18 | 13.03 | 5 | 48870 | 155 | 70879414 |
Calcium deficiency | 14.18 | 13.03 | 8 | 48867 | 768 | 70878801 |
Culture positive | 14.10 | 13.03 | 9 | 48866 | 1081 | 70878488 |
Radiation injury | 14.05 | 13.03 | 8 | 48867 | 782 | 70878787 |
Breast cancer male | 14.04 | 13.03 | 6 | 48869 | 314 | 70879255 |
Myomectomy | 14.02 | 13.03 | 3 | 48872 | 12 | 70879557 |
Alopecia | 13.90 | 13.03 | 80 | 48795 | 198410 | 70681159 |
Hip fracture | 13.89 | 13.03 | 47 | 48828 | 28216 | 70851353 |
Bone cancer | 13.89 | 13.03 | 11 | 48864 | 1857 | 70877712 |
Inner ear disorder | 13.78 | 13.03 | 7 | 48868 | 544 | 70879025 |
Drug withdrawal syndrome | 13.50 | 13.03 | 3 | 48872 | 32712 | 70846857 |
Clavicle fracture | 13.47 | 13.03 | 15 | 48860 | 3889 | 70875680 |
Carcinoid tumour | 13.37 | 13.03 | 7 | 48868 | 579 | 70878990 |
Wheezing | 13.37 | 13.03 | 28 | 48847 | 94142 | 70785427 |
Hysteroscopy | 13.32 | 13.03 | 3 | 48872 | 16 | 70879553 |
Extradural neoplasm | 13.32 | 13.03 | 3 | 48872 | 16 | 70879553 |
Injection site swelling | 13.30 | 13.03 | 62 | 48813 | 43095 | 70836474 |
Ovarian cyst ruptured | 13.30 | 13.03 | 8 | 48867 | 866 | 70878703 |
Traumatic fracture | 13.26 | 13.03 | 8 | 48867 | 870 | 70878699 |
Bradycardia | 13.15 | 13.03 | 43 | 48832 | 124572 | 70754997 |
Neovascular age-related macular degeneration | 13.07 | 13.03 | 6 | 48869 | 373 | 70879196 |
None
Source | Code | Description |
---|---|---|
ATC | L02AE02 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONES AND RELATED AGENTS Gonadotropin releasing hormone analogues |
ATC | L02AE51 | ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS ENDOCRINE THERAPY HORMONES AND RELATED AGENTS Gonadotropin releasing hormone analogues |
CHEBI has role | CHEBI:35610 | antineoplastic agents |
CHEBI has role | CHEBI:50751 | anti-estrogenic drug |
CHEBI has role | CHEBI:63533 | gonadotropin releasing hormone agonists |
FDA MoA | N0000175654 | Gonadotropin Releasing Hormone Receptor Agonists |
FDA EPC | N0000175655 | Gonadotropin Releasing Hormone Receptor Agonist |
MeSH PA | D000970 | Antineoplastic Agents |
MeSH PA | D018931 | Antineoplastic Agents, Hormonal |
MeSH PA | D005300 | Fertility Agents, Female |
MeSH PA | D012102 | Reproductive Control Agents |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Endometriosis | indication | 129103003 | |
Precocious puberty | indication | 400179000 | |
Anemia due to Bleeding Uterine Leiomyoma | indication | ||
Advanced Prostatic Carcinoma | indication | ||
Malignant tumor of ovary | off-label use | 363443007 | DOID:2394 |
Urinary tract obstruction | contraindication | 7163005 | DOID:5200 |
Hypercholesterolemia | contraindication | 13644009 | |
Myocardial infarction | contraindication | 22298006 | DOID:5844 |
Hypertensive disorder | contraindication | 38341003 | DOID:10763 |
Diabetes mellitus | contraindication | 73211009 | DOID:9351 |
Hyperglycemia | contraindication | 80394007 | DOID:4195 |
Cerebrovascular accident | contraindication | 230690007 | |
Orchiectomy | contraindication | 236334001 | |
Pregnancy, function | contraindication | 289908002 | |
Osteopenia | contraindication | 312894000 | |
Cardiovascular event risk | contraindication | 395112001 | |
Breastfeeding (mother) | contraindication | 413712001 | |
Obesity | contraindication | 414916001 | DOID:9970 |
Smokes tobacco daily | contraindication | 449868002 | |
Vertebral Metastases | contraindication |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 9.65 | acidic |
pKa2 | 11.9 | acidic |
pKa3 | 12.73 | acidic |
pKa4 | 13.09 | acidic |
pKa5 | 13.39 | acidic |
pKa6 | 13.69 | acidic |
pKa7 | 10.75 | Basic |
pKa8 | 6.69 | Basic |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Patent number | Patent expiration date | Patent use |
---|---|---|---|---|---|---|---|---|---|---|
22.5MG | ELIGARD KIT | TOLMAR THERAP | N021379 | July 24, 2002 | RX | POWDER | SUBCUTANEOUS | 8470359 | Oct. 15, 2023 | METHOD OF TREATING CANCER |
30MG | ELIGARD KIT | TOLMAR THERAP | N021488 | Feb. 13, 2003 | RX | POWDER | SUBCUTANEOUS | 8470359 | Oct. 15, 2023 | METHOD OF TREATING CANCER |
45MG | ELIGARD KIT | TOLMAR THERAP | N021731 | Dec. 14, 2004 | RX | POWDER | SUBCUTANEOUS | 8470359 | Oct. 15, 2023 | METHOD OF TREATING CANCER |
45MG | FENSOLVI KIT | TOLMAR | N213150 | May 1, 2020 | RX | POWDER | SUBCUTANEOUS | 8470359 | Oct. 15, 2023 | METHOD OF TREATING PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY |
45MG/VIAL | LUPRON DEPOT | ABBVIE ENDOCRINE INC | N020517 | June 17, 2011 | RX | INJECTABLE | INJECTION | 8921326 | Feb. 5, 2031 | PALLIATIVE TREATMENT OF PROSTATE CANCER |
Formulation strength | Trade name | Applicant | Application number | Approval date | Type | Dose form | Route | Exclusivity date | Description |
---|---|---|---|---|---|---|---|---|---|
45MG | FENSOLVI KIT | TOLMAR | N213150 | May 1, 2020 | RX | POWDER | SUBCUTANEOUS | May 1, 2023 | TREATMENT OF PEDIATRIC PATIENTS 2 YEARS OF AGE AND OLDER WITH CENTRAL PRECOCIOUS PUBERTY (CPP) |
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
Gonadotropin-releasing hormone receptor | GPCR | AGONIST | IC50 | 9.52 | WOMBAT-PK | CHEMBL | |||
Gonadotropin-releasing hormone receptor | GPCR | IC50 | 9.30 | CHEMBL |
ID | Source |
---|---|
4019800 | VUID |
N0000147889 | NUI |
D00989 | KEGG_DRUG |
74381-53-6 | SECONDARY_CAS_RN |
4018977 | VANDF |
4019800 | VANDF |
C0085272 | UMLSCUI |
CHEBI:6427 | CHEBI |
CHEMBL1201199 | ChEMBL_ID |
CHEMBL1200775 | ChEMBL_ID |
DB00007 | DRUGBANK_ID |
C493311 | MESH_SUPPLEMENTAL_RECORD_UI |
1175 | IUPHAR_LIGAND_ID |
657181 | PUBCHEM_CID |
203217 | RXNORM |
11929 | MMSL |
43716 | MMSL |
4966 | MMSL |
8763 | MMSL |
d01353 | MMSL |
002675 | NDDF |
004751 | NDDF |
008314 | NDDF |
008315 | NDDF |
350364005 | SNOMEDCT_US |
397198002 | SNOMEDCT_US |
70562007 | SNOMEDCT_US |
D016729 | MESH_DESCRIPTOR_UI |
CHEMBL4802223 | ChEMBL_ID |
5025 | INN_ID |
37JNS02E7V | UNII |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Leuprolide Acetate | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0185-7400 | INJECTION, SOLUTION | 1 mg | SUBCUTANEOUS | ANDA | 25 sections |